S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
How Much Longer Will It Be Under $1? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
NASDAQ:SLGL

Sol-Gel Technologies - SLGL Stock Forecast, Price & News

$5.99
-0.41 (-6.41%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.99
$6.26
50-Day Range
$4.10
$6.40
52-Week Range
$3.94
$10.91
Volume
4,044 shs
Average Volume
12,290 shs
Market Capitalization
N/A
P/E Ratio
14.61
Dividend Yield
N/A
Price Target
$18.33

Sol-Gel Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
206.1% Upside
$18.33 Price Target
Short Interest
Bearish
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.31) to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

SLGL stock logo

About Sol-Gel Technologies (NASDAQ:SLGL) Stock

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Analyst Ratings Changes

Separately, HC Wainwright lifted their target price on Sol-Gel Technologies from $20.00 to $21.00 and gave the company a "buy" rating in a report on Monday, April 25th.

Sol-Gel Technologies Trading Down 6.4 %

Shares of SLGL traded down $0.41 during mid-day trading on Friday, reaching $5.99. The company's stock had a trading volume of 4,044 shares, compared to its average volume of 12,290. The company's 50 day moving average is $5.15 and its 200 day moving average is $6.35. Sol-Gel Technologies has a 12-month low of $3.94 and a 12-month high of $10.91.

Sol-Gel Technologies (NASDAQ:SLGL - Get Rating) last released its quarterly earnings data on Friday, May 13th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. Sol-Gel Technologies had a net margin of 28.91% and a return on equity of 19.41%. As a group, equities research analysts expect that Sol-Gel Technologies will post -0.31 EPS for the current fiscal year.

Receive SLGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter.

SLGL Stock News Headlines

Sol-Gel Technologies Ltd. (SLGL)
See More Headlines
Receive SLGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter.

SLGL Company Calendar

Last Earnings
11/11/2021
Today
8/14/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLGL
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+206.1%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$3.22 million
Pretax Margin
28.91%

Debt

Sales & Book Value

Annual Sales
$31.27 million
Cash Flow
$0.19 per share
Book Value
$2.73 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.41

Key Executives

  • Dr. Alon Seri-Levy (Age 61)
    Co-Founder, CEO & Director
    Comp: $567k
  • Mr. Gilad Mamlok (Age 54)
    Chief Financial Officer
    Comp: $469k
  • Mr. Moshe Arkin (Age 69)
    Exec. Chairman
  • Prof. David Avnir
    Co-Founder
  • Dr. Itzik Yosef (Age 46)
    Chief Operating Officer
  • Dr. Karine Neimann (Age 51)
    VP of Projects & Planning and Chief Chemist













SLGL Stock - Frequently Asked Questions

Should I buy or sell Sol-Gel Technologies stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLGL shares.
View SLGL analyst ratings
or view top-rated stocks.

What is Sol-Gel Technologies' stock price forecast for 2022?

3 brokerages have issued 1 year price objectives for Sol-Gel Technologies' stock. Their SLGL share price forecasts range from $17.00 to $21.00. On average, they predict the company's share price to reach $18.33 in the next twelve months. This suggests a possible upside of 206.1% from the stock's current price.
View analysts price targets for SLGL
or view top-rated stocks among Wall Street analysts.

How have SLGL shares performed in 2022?

Sol-Gel Technologies' stock was trading at $7.40 at the start of the year. Since then, SLGL shares have decreased by 19.1% and is now trading at $5.99.
View the best growth stocks for 2022 here
.

When is Sol-Gel Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our SLGL earnings forecast
.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its quarterly earnings results on Thursday, November, 11th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.13. The business earned $8.84 million during the quarter, compared to analyst estimates of $9.53 million. Sol-Gel Technologies had a trailing twelve-month return on equity of 19.41% and a net margin of 28.91%.

What other stocks do shareholders of Sol-Gel Technologies own?

When did Sol-Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

What is Sol-Gel Technologies' stock symbol?

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Who are Sol-Gel Technologies' major shareholders?

Sol-Gel Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sol-Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $5.99.

How can I contact Sol-Gel Technologies?

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The official website for the company is www.sol-gel.com. The company can be reached via phone at (728) 931-3433, via email at crusso@soleburytrout.com, or via fax at 972-153-523044444.

This page (NASDAQ:SLGL) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.